Genomic complexity of multiple myeloma and its clinical implications (Q34537571)

2 August 2017

1 reference

title

Genomic complexity of multiple myeloma and its clinical implications (English)

1 reference

2 August 2017

1 reference

Gad Getz

0 references

Dan A Landau

series ordinal

object named as

Dan A Landau

1 reference

2 August 2017

Irene M Ghobrial

1 reference

2 August 2017

Salomon Manier

1 reference

2 August 2017

Karma Z Salem

series ordinal

1 reference

2 August 2017

Jihye Park

series ordinal

1 reference

2 August 2017

language of work or name

English

0 references

publication date

17 August 2016

1 reference

Nature Reviews Clinical Oncology

2 August 2017

published in

1 reference

2 August 2017

1 reference

2 August 2017

1 reference

2 August 2017

page(s)

100-113

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

2 August 2017

1 reference

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

A monoclonal gammopathy precedes multiple myeloma in most patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Initial genome sequencing and analysis of multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Familial risks and temporal incidence trends of multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Inherited genetic susceptibility to monoclonal gammopathy of unknown significance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Genetic factors influencing the risk of multiple myeloma bone disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Age has a profound effect on the incidence and significance of chromosome abnormalities in myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Induction of cell cycle regulatory proteins in anti-immunoglobulin-stimulated mature B lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

The molecular classification of multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Clinical and biologic implications of recurrent genomic aberrations in myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Ectopic expression of MAFB gene in human myeloma cells carrying (14;20)(q32;q11) chromosomal translocations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Molecular Dissection of Hyperdiploid Multiple Myeloma by Gene Expression Profiling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Hypodiploidy is a major prognostic factor in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

1q12 chromosome translocations form aberrant heterochromatic foci associated with changes in nuclear architecture and gene expression in B cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transpla

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Prognostic significance of copy-number alterations in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Genetic aberrations and survival in plasma cell leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

The landscape of somatic copy-number alteration across human cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Pan-cancer patterns of somatic copy number alteration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Mutational heterogeneity in cancer and the search for new cancer-associated genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Discovery and saturation analysis of cancer genes across 21 tumour types

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Signatures of mutational processes in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Mutational processes molding the genomes of 21 breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

ATM and ATR as therapeutic targets in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

A single subunit, Dis3, is essentially responsible for yeast exosome core activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

The exosome: a multipurpose RNA-decay machine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Clonal evolution in hematological malignancies and therapeutic implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Genetic variegation of clonal architecture and propagating cells in leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Darwinian evolution and tiding clones in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Absolute quantification of somatic DNA alterations in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

International staging system for multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Targeting the BRAF V600E mutation in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Clinical responses with T lymphocytes targeting malignancy-associated κ light chains

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Neoantigens in cancer immunotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Clonal evolution in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Hallmarks of Cancer: The Next Generation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Selective inhibition of BET bromodomains

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2016.122

Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities

31 March 2020

1 reference

12 December 2020

Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance

1 reference

12 December 2020

The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts

1 reference

12 December 2020

Regulation of the catalytic subunit (p34PSK-J3/cdk4) for the major D-type cyclin in mature B lymphocytes

1 reference

12 December 2020

Genomic abnormalities in monoclonal gammopathy of undetermined significance

1 reference

12 December 2020

Formation of a hyperdiploid karyotype in childhood acute lymphoblastic leukemia

1 reference

12 December 2020

Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myélome.

1 reference

12 December 2020

Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines.

1 reference

12 December 2020

Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.

1 reference

12 December 2020

14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myélome

1 reference

12 December 2020

The genetic architecture of multiple myeloma

1 reference

12 December 2020

Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin

1 reference

12 December 2020

10.1038/NRCLINONC.2016.122

Identifiers

DOI

1 reference

2 August 2017

1 reference